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PURPOSE. Genetic variants in genes encoding components of lipid metabolism have been
associated with AMD. The aims of this study were to evaluate the relation of these genetic
variants with serum lipid levels in AMD in a large case-control cohort (n ¼ 3070) and to test
for correlations between lipids and complement activation.
METHODS. Single nucleotide polymorphisms (SNPs) in eight lipid metabolism genes, previously
described to be associated with AMD, were genotyped and tested for their association in our
case-control cohort. Serum apolipoprotein B (ApoB), apolipoprotein AI (Apo-AI), cholesterol,
triglycerides (TG), high-density lipoprotein–cholesterol (HDLC), and complement activation
levels (C3d/C3) were measured and tested for association with AMD. Non-HDL cholesterol
and LDL were inferred based on the measurements of the other lipids and lipoproteins.
General linear models and v2 tests were used to evaluate the relation of SNPs and lipids/
lipoproteins to the disease as well as their interrelations.
RESULTS. Significant genotypic associations with AMD were observed for SNPs in CETP, APOE,
and FADS1. The serum levels of Apo-AI and HDLC were significantly higher in patients
compared with controls. Triglycerides (TG) levels were lower in AMD compared with
controls. A cumulative effect was observed for APOE and CETP genotypes on HDLC and Apo-
AI levels. Complement activation levels correlated positively with HDLC and Apo-AI, and
negatively with TG. Both the lipids/lipoproteins and the complement activation levels
associate independently to AMD.
CONCLUSIONS. This study bridges the gap between genetic associations and physiological lipid
levels in AMD. Additionally, the observed correlations between complement activation and
lipid levels link two major systems that previously were always assessed independently.
Keywords: SNP, lipoprotein, AMD, complement system, lipids
Age-related macular degeneration (AMD) is a multifactorial,progressive disease and a leading cause of blindness in the
elderly population.1,2 The strong genetic underpinnings of
AMD based on genome-wide association studies (GWAS)
broadly point toward the involvement of three systems in the
pathogenesis of AMD: the complement system, lipid metabo-
lism, and the extracellular matrix.3 Investigating the pathways
identified by genetic associations has proven to be a fruitful
research strategy in the past. A higher rate of systemic
complement activation levels was demonstrated in patients
compared with controls,4,5 bringing systemic physiological
consequences in line with the genetic associations. For the
second major system involved in AMD, the lipid metabolism,
such congruency is not immediately apparent.
Lipids, due to their insoluble nature, are transported
through the circulation by lipoproteins.6 Two major lipopro-
teins of this process are low-density lipoprotein (LDL) and high-
density lipoprotein (HDL).7 Low-density lipoprotein is respon-
sible for transporting cholesterol from the liver to the
periphery, while HDL transports peripheral cholesterol back
to the liver in a process called reverse cholesterol transport
(RCT).8
In a recent GWAS on AMD, three genes involved in the
lipoprotein transport system (CETP, APOE, and LIPC) reached
genome-wide significance.3 In addition, two earlier association
studies also reported associations for LPL, FADS1, and
ABCA1.9,10 All of the proteins encoded by these genes, are
either enzymes, coenzymes, or transporters within the lipid
metabolism. Thus, ample genetic evidence exists for the
involvement of lipid metabolism in the etiology of AMD.
In the pathology of AMD, aberrant lipid homeostasis has also
been observed. Particularly, approximately 40% of drusen
composition (one of the major hallmarks of AMD) is made up
of esterified cholesterol, unesterified cholesterol, and phospha-
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tidylcholine.11 However, it has proven to be challenging to
attribute risk scores for the development of AMD to systemic
measurements of HDL or LDL. Studies directly investigating the
levels of HDL/HDLC and LDL report conflicting results, with
some presenting higher levels of HDL/HDLC in AMD patients
compared with controls,12–18 whereas others describe the
opposite.19–21 Yet other reports, including those that com-
bined multiple of the previous studies, did not observe any
significant differences between patients and controls.1,22–26
It is important to clarify the role of HDL and other lipids/
lipoproteins in AMD and their relation to the established AMD-
associated lipid genes, as this may shed more light on the
pathogenesis of AMD. Such insights potentially could lead to
targeted and more efficient approaches toward treatment
regimens for AMD. Therefore, the primary aim of this study
was to investigate the relation of single nucleotide polymor-
phisms (SNPs) genotypes in the AMD-associated lipid genes
and serum lipid levels in AMD in a large case-control cohort (N
¼ 3070). The secondary aim was to determine if there is a
correlation between the previously described complement
activation4 and lipid levels.
METHODS
Study Population
From the European Genetic Database (EUGENDA, in the public
domain, www.eugenda.org), 3070 participants above the age
of 50 years were included in the study. The study was
performed in accordance with the tenets of the Declaration of
Helsinki and the Medical Research Involving Human Subjects
Act (WMO), and was approved by the local ethics committee
of the University Hospitals in Cologne and Nijmegen. Written
informed consent was obtained from all participants.
Age-related macular degeneration and control status were
assigned by multimodal image grading that included stereo
fundus photographs, fluorescein angiograms, and spectral-
domain optical coherence tomograms. The grading was
performed according to the standard protocol of the Cologne
Image Reading Center (CIRCL) by certified graders (TR, LE).
The classification of AMD was performed as described
previously.27
Demographic data and nongenetic parameters including
smoking status (current/past/never), regular alcohol intake
(current/past/never), body mass index (BMI), exercise/physi-
cal activity (never, almost never, 1–2 times a week, 3 or more
times a week), and daily fat consumption (more than 35 g oil
per day: Yes/No) were obtained by standardized interviewer-
assisted questionnaires.
Serum Measurements and Genetic Analysis
Serum samples were used for the various lipid and systemic
complement measurements. Serum was obtained by a standard
coagulation/centrifugation protocol, after which the samples
were stored at 808C within 1 hour after collection. Serum
levels of apolipoprotein B (Apo-B), apolipoprotein AI (Apo-AI),
total cholesterol, triglycerides (TG), and HDL-cholesterol
(HDLC) were measured in all patients and controls using
standard procedures by a clinical chemistry laboratory
(Architect Analyzer; Abbott Diagnostics Hoofddorp, The
Netherlands). Non-HDL cholesterol (NHDL) was calculated
by subtracting HDLC from total cholesterol; and low-density
lipoprotein (LDL) cholesterol was calculated using the
Friedewald formula.28
Complement component C3 and the activation fragment
C3d were measured in serum samples as previously de-
scribed29 and C3d/C3 was calculated as a measure of
complement activation.
Genomic DNA was extracted from peripheral blood
samples using standard procedures. Eight SNPs in the LIPC,
CETP, APOE, FADS1, LPL, and ABCA1 genes (see
Supplementary Table S1) were genotyped using the KASPar
SNP Genotyping System by LGC Genomics.
Statistical Analysis
All calculations were performed using SPSS software version
20.0 (IBM Software and Systems, Armonk, NY, USA). Associ-
ations between lipid levels, SNP genotypes and disease status
were analyzed using general linear models with each lipid, in
turn, set as the dependent variable. The first model was built to
find the association between lipids and disease status, the
model was corrected for all possible confounders (see Table 3).
The second model was built to find the association between
lipids and SNP’s, again the model corrected for all possible
confounders (see Table 4). In literature smoking status, alcohol
intake, BMI, and dietary fat intake are reported to significantly
influence lipid and lipoprotein levels,30–34 for this reason they
were selected as correction factors for the models to eliminate
any possible confounding. Additionally, age, sex, and exercise/
physical activity were significantly different between patients
and controls, thus they were also added as correction factors.
In order to assess the cumulative effect of CETP and APOE
SNPs on lipid/lipoprotein levels, a new variable was created
that had all nine possible genotype combinations (see Table 4).
The association with the lipid/lipoprotein levels was tested in a
general linear model also corrected for age, sex, BMI, smoking
status, alcohol intake, exercise/physical activity, daily fat
consumption, and disease status. The significance threshold
was corrected for multiple testing, P values less than or equal
to 0.006 (0.05/8 associations per experiment) were considered
statistically significant for the associations to AMD of both SNP
genotypes and serum lipid levels. For the associations of the
SNPs and serum lipid levels we have corrected for 12
associations (4 genetic variables against 3 lipid/lipoprotein
levels). The P values less than or equal to 0.004 (0.05/12
studied associations) were considered significant.
Associations between AMD phenotype and genotypes were
evaluated using cross tabulation, P values were calculated with
Pearson v2 and odds ratios were generated using logistic
regression. Pearson correlations were used to investigate the
relationship between lipids and complement activation levels.
All power calculations were performed using CaTS - Power
Calculator v0.0.2 (Center for Statistical Genomics, University of
Michigan, Ann Arbor, MI, USA) as previously described.35 For
the calculation we assumed a multiplicative model, a disease
prevalence of 10% and a significance level of 0.006 (0.05/8
SNPs). The disease allele frequency and genotype relative risk
were extracted from the papers that first described the
associations (Supplementary Table S1).
RESULTS
Summary of the demographics for the subjects included in the
present study are shown in Table 1.
Eight SNPs in genes of the lipid metabolism, previously
shown to be associated with AMD, were selected from
literature (see Supplementary Table S1). Out of the eight SNPs
that were analyzed, genotypes in CETP (rs3764261; P¼ 0.002),
APOE (rs4420638; P ¼ 0.005), and FADS1 (rs174547; P ¼
0.005), were significantly associated with AMD after correcting
for multiple testing (P < 0.006). A summary of all associations
and genotype frequencies are presented in Table 2.
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Mean serum levels of Apo-B, Apo-AI, total cholesterol,
HDLC, LDL, NHDL, and triglycerides of AMD patients
compared to controls are presented in Table 3. After adjusting
for age, sex, BMI, smoking status, alcohol intake, exercise/
physical activity, and daily fat consumption, AMD patients had
significantly higher Apo-AI (P ¼ 0.002) and HDLC levels (P ¼
4.4 3 105) compared with controls. In contrast, patients had
significantly lower serum levels of TG (P ¼ 1.9 3 104)
compared with controls. Significant positive correlations were
observed between Apo-AI and HDLC, and negative correlations
between HDLC and TG (Supplementary Fig. S1). The
association between Apo-AI and AMD was independent of
HDLC and TG. Similarly, the association of TG with AMD was
independent of HDLC and Apo-AI. When correcting for Apo-AI
and TG, the association of HDLC with AMD was negated,
which is in line with the correlation of HDLC with Apo-AI and
TG levels. No significant associations were found for any of the
other measurements.
Stratifying for the different AMD stages revealed significant
associations only with the intermediate AMD stage. The
observed effect directions were similar to the comparison of
all AMD stages versus controls, with only Apo-AI, HDLC, and
TG being significantly associated with intermediate AMD after
correction for multiple testing (Supplementary Table S2).
The SNPs that were significantly associated with AMD in the
EUGENDA cohort, were analyzed for association with the lipid/
lipoprotein levels that significantly differed between patients
and controls. Only APOE (rs4420638) and CETP (rs3764261)
genotypes displayed significant associations with Apo-AI and
HDLC serum levels. APOE (rs4420638) genotypes were
moderately associated with TG levels (P ¼ 0.026), however
the association did not remain significant after correcting for
multiple testing. A summary of the results is presented in Table
4.
Because both CETP and APOE SNP genotypes were
significantly associated with Apo-AI and HDLC serum levels,
TABLE 1. Baseline Characteristics of Study Subjects
EUGENDA
AMD,
n ¼ 1491
Control,
n ¼ 1579
Female sex, % 60 58
Mean age 6 SD, y 74.7 6 8.4 69 6 7.6
Age range, y 50–101 50–100
Mean BMI 6 SD 25.82 6 3.8 25.79 6 3.9
Smoking status, %
Current 10.2 8.5
Past 47.6 47.5
Never 42.2 44
Regular alcohol intake, %
Current 57.6 56.4
Past 5 4.2
Never 37.4 39.4
Exercise/physical activity, %
Never 24 20.1
Almost never 14.6 6.8
1–2 times a week 44.2 47
3 or more times a week 17.2 26.1
Daily fat consumption, %
Yes 28.8 30.6
No 71.2 69.4
Significant differences between the two groups were only for age (P
¼1.98310114), sex (P¼0.043), and exercise/physical activity (P¼9.9
3 1025).
TABLE 2. Association of Genotypes in Lipid Metabolism Genes With AMD
SNP Gene P* Genotype
Status, %
OR 95% CIControl AMD
rs493258 LIPC 0.388 TT 21.1 19.6
CT 49.0 48.6 1.07 0.89–1.27
CC 29.9 31.8 1.14 0.94–1.38
rs10468017 LIPC 0.161 TT 8.2 7.7
CT 41.9 39.1 0.99 0.76–1.28
CC 49.9 53.2 1.13 0.88–1.46
rs3764261 CETP 0.002 GG 47.8 42.3
GT 41.2 44.2 1.21 1.05–1.40
TT 10.9 13.5 1.40 1.12–1.74
rs2075650 APOE 0.043 GG 1.6 1.4
GA 23.5 20.1 0.96 0.54–1.69
AA 74.9 78.5 1.18 0.68–2.05
rs4420638 APOE 0.005 GG 3.0 1.9
GA 28.6 25.3 1.41 0.89–2.21
AA 68.3 72.8 1.70 1.09–2.65
rs12678919 LPL 0.579 AA 80.7 79.3
AG 18.1 19.4 1.10 0.92–1.30
GG 1.3 1.2 0.99 0.54–1.81
rs174547 FADS1 0.005 CC 11.8 8.5
CT 43.1 43.8 1.41 1.12–1.79
TT 45.1 47.7 1.47 1.16–1.86
rs3758294 ABCA1 0.982 TT 63.1 62.9
TC 32.6 32.8 1.03 0.73–1.45
CC 4.3 4.2 1.02 0.73–1.42
* After correction for multiple testing significance is reached at P  0.006.
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the cumulative effect of carrying multiple risk genotypes on
the lipid levels was investigated. Mean levels for each genotype
combination of CETP and APOE are displayed in Table 4 and
visualized in Figure 1. In both cases, carriers of double high-risk
genotypes for CETP and APOE showed significantly elevated
levels of Apo-AI and HDLC compared with low-risk genotype
carriers.
To exclude the possibility that the associations of HDLC and
Apo-AI with AMD were mainly a consequence of the
underlying genetic associations of CETP and APOE that drive
HDLC and Apo-AI levels, all lipid analyses were corrected for
CETP and APOE genotypes and all the other genotyped SNPs.
After doing so, HDLC and Apo-AI remained significantly
associated with AMD, independent of the genotypes (P ¼ 1.4
3 104 and 0.003, respectively)
Finally, because serum complement activation levels were
previously shown to be associated to AMD,4 we tested whether
a relation exists between lipid levels and complement
activation levels (C3d/C3 ratio). This analysis revealed signif-
icant positive correlations between Apo-AI, HDLC, and
complement activation and a significant negative correlation
for TG (Fig. 2). All P values were less than 1.93109. A general
linear model corrected for disease status and other variables
confirmed the association of C3d/C3 to lipids/lipoproteins (P¼
< 1.93109) and revealed that the association to disease status
is independent of lipid levels (P ¼ 9 3 106).
DISCUSSION
The genetic analyses from the present case-control study
confirm previously described associations for CETP
(rs3764261), APOE (rs4420638), and FADS1 (rs174547) with
AMD. However, no associations were observed for APOE
(rs2075650), LIPC (rs493258 and rs10468017), LPL
(rs12678919), and ABCA1 (rs3758294). The SNPs were
selected from recent large GWAS3 , 9 , 1 0 , 3 6 , 3 7 (see
Supplementary Table S1). For the SNPs in ABCA1
(rs1883025) and LIPC (rs493258 and rs10468017) our study
was underpowered with 52%, 59%, and 53% chance of
detection, respectively. Therefore, we cannot exclude the
possibility that these SNPs may be associated to AMD in a larger
cohort. On the other hand, for LPL (rs12678919) this study had
TABLE 3. Association of Mean Serum Lipid/Lipoprotein Levels With
AMD
Lipid Status Mean SE P
Apo-B, mg/L Control 954.98 9.50 0.788
AMD 957.44 9.41
Apo-AI, mg/L Control 1615.76 11.43 0.002
AMD 1649.35 11.32
Total cholesterol, mM Control 5.60 0.05 0.155
AMD 5.66 0.05
HDLC, mM Control 1.40 0.01 4.6 3 105
AMD 1.45 0.01
LDL, mM Control 3.83 0.04 0.739
AMD 3.85 0.04
NHDL, mM Control 4.20 0.05 0.819
AMD 4.21 0.04
TG, mM Control 1.76 0.03 1.9 3 104
AMD 1.65 0.03
General linear models were built with each lipid/lipoprotein as the
dependent variable. The models tested for the association to disease
status and were all corrected for age, sex, BMI, smoking status, alcohol
intake, exercise/physical activity and daily fat consumption. Threshold
for statistical significance P < 0.006.
TABLE 4. Association of AMD SNPs With Serum Lipid/Lipoprotein Levels
Lipid/Lipoprotein
Apo-AI, mg/L HDLC, mM TG, mM
SNP Genotype Mean SE Mean SE Mean SE
CETP rs3764261 GG 1601.6 12.1 1.37 0.01 1.71 0.03
GT 1645.9 12.0 1.46 0.01 1.71 0.03
TT* 1704.6 17.8 1.54 0.02 1.73 0.05
Sig. 2.8 3 109 6.50 3 1020 0.950
APOE rs4420638 GG 1555.7 35.9 1,32 0.04 1.95 0.09
GA 1612.6 13.8 1.42 0.02 1.73 0.04
AA* 1643.6 11.0 1.44 0.01 1.71 0.03
Sig. 0.003 0.012 0.026
FADS1 rs174547 CC 1620.4 18.6 1.44 0.02 1.75 0.05
TC 1632.8 12.1 1.43 0.01 1.74 0.03
TTa 1638.5 12.0 1.43 0.01 1.69 0.03
Sig. 0.595 0.832 0.137
CETP/APOE GG/GG 1531.3 48.8 1.26 0.06 2.1 0.13
GG/GA 1561.4 18.0 1.33 0.02 1.7 0.05
GG/AA 1619.0 13.1 1.39 0.02 1.7 0.04
GT/GG 1590.9 54.6 1.41 0.06 1.8 0.14
GT/GA 1651.7 18.2 1.48 0.02 1.7 0.05
GT/AA 1644.2 13.0 1.45 0.02 1.7 0.03
TT/GG 1530.6 123.3 1.29 0.14 2.2 0.36
TT/GA 1660.3 29.7 1.51 0.03 1.8 0.08
TT/AA 1725.3 20.7 1.56 0.02 1.7 0.05
Sig. 1.3 3 109 4.4 3 1019 0.118
The model was corrected for age, sex, BMI, smoking status, alcohol intake, exercise/physical activity, daily fat consumption, and disease status.
Threshold for statistical significance P < 0.004. Sig., significance.
* Risk allele for AMD in our cohort.
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77% detection power, suggesting that not all genetic associa-
tions may be reliably replicated between different populations.
In this study, we observed significant differences in the
serum levels of Apo-AI, HDLC, and TG of AMD patients
compared with controls. Triglycerides were significantly lower,
while Apo-AI and HDLC were significantly higher in patients
compared with controls. No statistically significant associations
with AMD were detected for any of the other measured lipids/
lipoproteins.
In the literature, there are inconsistent associations of AMD
with serum lipid levels. Comparing the mean lipid/lipoprotein
levels observed in the present study with values previously
reported (Supplementary Table S3), is challenging since the
measurements were performed differently across the various
reports, different correction factors were applied, and different
populations were studied. All of these factors can influence the
mean levels, making it difficult to pinpoint the cause of the
different study outcomes. However, if we compare the main
effects, our findings of high HDLC levels in patients compared
with controls are consistent with several previous studies.12–18
The positive association of HDLC with only the intermediate
AMD stage confirms the finding reported by Cougnard-
Gre´goire et al.12 On the other hand, other publications have
reported inverse or no association between HDLC and
AMD.19–23,25,26 When results were pooled in a meta-analysis,
no associations have been detected.1,24,38 To our knowledge,
for Apo-AI this is the first large study to report a positive
association with AMD, and for TG other studies reported
opposite or no associations with AMD.12,20,26 The reasons for
these inconsistencies are not fully understood, however in a
recent publication high levels of HDLC were associated with
risk for AMD only after a stringent multivariate correction.12
Because our study, and others,39–41 show a clear effect of
genotype on lipid levels, correcting for these genotypes may
improve the insight into the associations of lipid levels with
AMD and the direction of their effect. This is especially
important because our study, although appropriately powered,
had failed to detect associations with LPL (rs12678919),
suggesting that population- or cohort-specific genetic substruc-
tures may account partly for the observed inconsistencies.
Another reason could be related to sample size, which in some
studies might not be large enough to allow for the necessary
adjustments and still have sufficient power to detect significant
associations. In our cohort, higher levels of Apo-AI and HDLC
were associated with risk genotypes in CETP (rs3764261; TT)
and APOE (rs4420638; AA). A cumulative effect was observed
for these two SNPs, with a risk-allele dose dependent increase
in both HDLC and Apo-AI serum levels (Fig. 1). The CETP and
APOE loci have previously been linked to lipid metabolism in
cardiovascular studies.40 In the context of AMD, few studies
have looked into the relation of AMD lipid SNPs and serum
lipid levels. Our results for CETP were consistent with a recent
report from the Alienor study.12 Another study observed that in
individuals carrying the LPL (rs12678919) GG genotype, TG
levels were significantly lower and HDLC levels were
significantly higher.42 Moreover, one study reported that the
LIPC (rs10468017) T allele was associated with higher levels of
HDLC.43 Our study does not describe an association of LPL and
LIPC genotypes with lipid levels, because no significant
difference between patients and controls was observed.
CETP encodes for cholesterol ester transfer protein (CETP),
which promotes the transfer of excess cholesterol ester (CE) to
the liver through the RCT pathway.44 Several studies have
shown that lower CETP activity leads to higher HDLC
levels.41,45,46 APOE encodes for apolipoprotein E (ApoE),
which plays a major role in the metabolism of cholesterol
and TG by mediating the clearance of chylomicrons and very
low-density–lipoprotein (VLDL) from the bloodstream.47,48
ApoE has been described to have a direct relation with CETP
by enhancing the CE and TG transfer between VLDL and HDL
in a CETP-dependent manner.49 Despite the direct impact of
APOE and CETP on HDLC metabolism, understanding how the
FIGURE 1. Mean lipid levels with standard error bars for CETP/APOE homozygous high-risk genotypes, heterozygous and homozygous low-risk
genotypes. All P values are Bonferroni-corrected. (A) Levels for Apo-AI; (B) levels for HDLC.
FIGURE 2. Scatterplots showing the correlations of lipid levels with complement activation levels represented by the log transformed ratio of C3d/
C3. Direction of the correlations is indicated by the black regression line. (A) Positive correlation of Apo-AI and logC3d/C3; (B) positive correlation
of HDLC with logC3d/C3; (C) negative correlation of TG and logC3d/C3.
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risk genotypes of the studied SNPs could have the cumulative
HDLC raising effect is not directly obvious, mainly because
both rs3764261 and rs4420638 are located in intergenic
regions. One possibility may be a consequence of an effect
on CETP expression levels that was reported for rs3764261.50
Traditionally, rs4420638 is reported as an APOE SNP,
because it is considered a proxy for rs429358, one of the
two coding variants that determine the APOE isoforms (e2, e3,
and e4) reported to attenuate binding affinity to the (LDL)-
receptor,51 and thus affect the entire cholesterol metabolism.
However, the r2 value for the linkage disequilibrium of these
two SNPs is 0.63,3 indicating that there is not a complete
coinheritance. Also its genomic position is closer to the APOC1
gene, a potent inhibitor of CETP activity,52 thus we cannot
exclude the possibility of rs4420638 for being a proxy for a
regulatory variant of APOC1 instead.
Understanding the local involvement of lipid and lipopro-
tein systems at AMD disease sites in the eye is made difficult by
the lack of information regarding eye specific function of these
molecules. Nevertheless, if we focus on HDLC metabolism,
clues can be found. First, key components of the RCT pathway
for which the main player is HDLC,53 are expressed in the
retina.54–56 In addition, during the normal aging process, an
accumulation of Apo-B of unusual composition takes place in
the Bruch’s membrane, forming a precursor of basal linear
deposit, called the ‘‘lipid wall.’’57 Moreover, the macromolec-
ular conductivity of the Bruch’s membrane reduces 10-fold
between the first and ninth decades of life, which is significant
because lipoproteins need to cross the Bruch’s membrane in
order to mediate lipid efflux from the RPE.58,59 Furthermore, in
vitro, HDL has been observed to mediate efflux of photore-
ceptor outer segment lipids from the basal surfaces of RPE
cells.60 Finally, a retention of cholesterol in drusen, the major
lesions of AMD, has been reported.61
Besides the involvement of HDL in lipid and lipoprotein
transport, this system has recently been implicated in immune
function.62 Recent proteomic analyses revealed several types
of HDL particles containing complement system components
C4a, C4b, C9, and vitronectin63,64 in healthy subjects, and C3
in patients with coronary artery disease.63 In our study, we
offer support for this emerging concept by demonstrating a
significant correlation between HDLC and complement system
activation, although it remains to be determined whether the
effect is direct or indirect.
One possible limitation of our study may be that the lipid/
lipoprotein levels were not overnight fasted blood measure-
ments, which could induce possible artifacts for certain lipids
like the TG. However, the fact that HDLC and Apo-AI levels are
not severely affected by food intake,65 and the great number of
participants in this study, negate this potential drawback.
In our study, the genetic and environmental factors explain
31%, 84%, and 27% of the Apo-AI, HDLC, and TG variation,
respectively. Our findings indicate that other factors must be
associated with them, which might relate to the AMD disease
pathogenesis.
In conclusion, the results of our study indicate that patients
with high risk CETP/APOE genotypes and high HDLC levels
have higher risk of developing AMD, suggesting that they could
potentially benefit from HDLC lowering regimens. Further
studies are needed to investigate the role of HDL subfractions
and the observed correlation of HDLC with complement
activation in the disease pathogenesis of AMD.
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